Original Research
Published on 05 Jan 2022
Induction Therapy Followed by Surgery for Unresectable Thymic Epithelial Tumours
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.791647
- 1,693 views
- 4 citations
- Frontiers in Oncology
- Thoracic Oncology
- Articles
Type at least 3 characters
1,534 articles
Articles
Original Research
Published on 04 Jan 2022
Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.766939
- 4,663 views
- 12 citations
Review
Published on 03 Jan 2022
Imaging Evaluation of Thymoma and Thymic Carcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.810419
- 27,637 views
- 26 citations
Mini Review
Published on 24 Dec 2021
Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.787585
- 15,409 views
- 27 citations
Systematic Review
Published on 23 Dec 2021
Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.774131
- 2,677 views
- 17 citations
Original Research
Published on 23 Dec 2021
A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.788837
- 1,947 views
- 1 citation
Review
Published on 23 Dec 2021
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.792385
- 4,086 views
- 1 citation
Original Research
Published on 21 Dec 2021
“How Long Have I Got?” in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.761042
- 126,122 views
- 11 citations
Original Research
Published on 16 Dec 2021
A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.722106
- 1,900 views
- 4 citations
Original Research
Published on 15 Dec 2021
YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.702491
- 3,924 views
- 14 citations
Review
Published on 15 Dec 2021
KRAS Mutations in Squamous Cell Carcinomas of the Lung
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.788084
- 8,824 views
- 14 citations
Review
Published on 15 Dec 2021
EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.766659
- 6,355 views
- 13 citations
Original Research
Published on 14 Dec 2021
An External-Validated Algorithm to Predict Postoperative Pneumonia Among Elderly Patients With Lung Cancer After Video-Assisted Thoracoscopic Surgery
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.777564
- 2,507 views
- 11 citations
Original Research
Published on 14 Dec 2021
Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.564234
- 2,990 views
- 3 citations
Original Research
Published on 14 Dec 2021
High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.747692
- 2,321 views
- 3 citations
Original Research
Published on 14 Dec 2021
Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.769037
- 2,450 views
- 1 citation